Edition:
United Kingdom

Alembic Pharmaceuticals Ltd (ALEM.NS)

ALEM.NS on National Stock Exchange of India

500.45INR
20 Apr 2018
Change (% chg)

Rs-0.25 (-0.05%)
Prev Close
Rs500.70
Open
Rs502.00
Day's High
Rs504.95
Day's Low
Rs498.30
Volume
26,149
Avg. Vol
81,902
52-wk High
Rs634.00
52-wk Low
Rs469.85

Select another date:

Mon, Apr 9 2018

BRIEF-Alembic Pharmaceuticals Gets U.S. FDA Nod For Acyclovir Ointment USP, 5 Pct

* SAYS CO RECEIVED U.S. FDA APPROVAL FOR ACYCLOVIR OINTMENT USP, 5 PERCENT Source text - http://bit.ly/2qiUKur Further company coverage:

BRIEF-Alembic Pharmaceuticals Says U.S FDA Issued 3 Observations For Panelav Formulation Facility

* SAYS U.S FDA CONDUCTED INSPECTION AT FORMULATION FACILITY AT PANELAV FROM 12 MARCH, 2018 TO 20 MARCH, 2018

BRIEF-India's Alembic Pharmaceuticals Dec Qtr Consol PAT Rises

* DEC QUARTER CONSOL NET PAT 1.31 BILLION RUPEES VERSUS 843.9 MILLION RUPEES YEAR AGO

BRIEF-Alembic Pharmaceuticals Says U.S. FDA Grants Orphan-Drug Designation To Rhizen Pharmaceuticals

* U.S. FDA GRANTS ORPHAN-DRUG DESIGNATION FOR TENALISIB TO RHIZEN PHARMACEUTICALS S.A. (RHIZEN) Source text - http://bit.ly/2C7DIYd Further company coverage:

BRIEF-Alembic Pharma Gets U.S. FDA Nod For Generic Drug to Treat Overactive Bladder

* DRUG IS INTENDED TO TREAT OVERACTIVE BLADDER Source text: http://bit.ly/2BVyJWK Further company coverage:

BRIEF-India's Alembic Pharma Sept-qtr consol PAT rises

* Says U.S. formulations business continues to face price erosion on some key products; India branded business showing signs of recovery‍​‍​

BRIEF-Alembic Pharma buys generic drug developer Orit Laboratories

* Says ‍co buys U.S. based generic drug developer Orit Laboratories LLC​ Source text: http://bit.ly/2z3AKCI Further company coverage:

Select another date: